

Global Anti-VEGF Intravitreal Drugs Market Growth 2024-2030

<https://marketpublishers.com/r/GA883749D865EN.html>

Date: November 2024

Pages: 97

Price: US\$ 3,660.00 (Single User License)

ID: GA883749D865EN

Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

Anti-VEGF intravitreal drugs refer to a class of medications used in ophthalmology to treat various eye conditions characterized by abnormal blood vessel growth and leakage, notably wet age-related macular degeneration (AMD), diabetic retinopathy, and macular edema, which work by blocking VEGF. These medications help reduce the growth of abnormal blood vessels, decrease vascular leakage, and thereby stabilize or improve vision.

The global Anti-VEGF Intravitreal Drugs market size is projected to grow from US\$ million in 2024 to US\$ million in 2030; it is expected to grow at a CAGR of % from 2024 to 2030.

LP Information, Inc. (LPI) ' newest research report, the "Anti-VEGF Intravitreal Drugs Industry Forecast" looks at past sales and reviews total world Anti-VEGF Intravitreal Drugs sales in 2023, providing a comprehensive analysis by region and market sector of projected Anti-VEGF Intravitreal Drugs sales for 2024 through 2030. With Anti-VEGF Intravitreal Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Anti-VEGF Intravitreal Drugs industry.

This Insight Report provides a comprehensive analysis of the global Anti-VEGF Intravitreal Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Anti-VEGF Intravitreal Drugs portfolios and capabilities, market entry strategies, market

positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Anti-VEGF Intravitreal Drugs market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Anti-VEGF Intravitreal Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Anti-VEGF Intravitreal Drugs.

United States market for Anti-VEGF Intravitreal Drugs is estimated to increase from US\$ million in 2023 to US\$ million by 2030, at a CAGR of % from 2024 through 2030.

China market for Anti-VEGF Intravitreal Drugs is estimated to increase from US\$ million in 2023 to US\$ million by 2030, at a CAGR of % from 2024 through 2030.

Europe market for Anti-VEGF Intravitreal Drugs is estimated to increase from US\$ million in 2023 to US\$ million by 2030, at a CAGR of % from 2024 through 2030.

Global key Anti-VEGF Intravitreal Drugs players cover Roche, Novartis, Biogen, Coherus BioSciences, Regeneron Pharmaceuticals, etc. In terms of revenue, the global two largest companies occupied for a share nearly

% in 2023.

This report presents a comprehensive overview, market shares, and growth opportunities of Anti-VEGF Intravitreal Drugs market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

Ranibizumab

Aflibercept

Conbercept

Brolucizumab

Faricimab

Other

Segmentation by Application:

Age-related Macular Degeneration

Diabetic Macular Edema

Retinal Vein Occlusion

Other

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.

Roche

Novartis

Biogen

Coherus BioSciences

Regeneron Pharmaceuticals

Samsung Bioepis

Biocon Biologics

Qilu Pharma

Chengdu Kanghong Pharmaceutical

Key Questions Addressed in this Report

What is the 10-year outlook for the global Anti-VEGF Intravitreal Drugs market?

What factors are driving Anti-VEGF Intravitreal Drugs market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Anti-VEGF Intravitreal Drugs market opportunities vary by end market size?

How does Anti-VEGF Intravitreal Drugs break out by Type, by Application?

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview

2.1.1 Global Anti-VEGF Intravitreal Drugs Annual Sales 2019-2030

2.1.2 World Current & Future Analysis for Anti-VEGF Intravitreal Drugs by Geographic Region, 2019, 2023 & 2030

2.1.3 World Current & Future Analysis for Anti-VEGF Intravitreal Drugs by Country/Region, 2019, 2023 & 2030

2.2 Anti-VEGF Intravitreal Drugs Segment by Type

2.2.1 Ranibizumab

2.2.2 Aflibercept

2.2.3 Conbercept

2.2.4 Brolucizumab

2.2.5 Faricimab

2.2.6 Other

2.3 Anti-VEGF Intravitreal Drugs Sales by Type

2.3.1 Global Anti-VEGF Intravitreal Drugs Sales Market Share by Type (2019-2024)

2.3.2 Global Anti-VEGF Intravitreal Drugs Revenue and Market Share by Type (2019-2024)

2.3.3 Global Anti-VEGF Intravitreal Drugs Sale Price by Type (2019-2024)

2.4 Anti-VEGF Intravitreal Drugs Segment by Application

2.4.1 Age-related Macular Degeneration

2.4.2 Diabetic Macular Edema

2.4.3 Retinal Vein Occlusion

2.4.4 Other

2.5 Anti-VEGF Intravitreal Drugs Sales by Application

2.5.1 Global Anti-VEGF Intravitreal Drugs Sale Market Share by Application (2019-2024)

2.5.2 Global Anti-VEGF Intravitreal Drugs Revenue and Market Share by Application (2019-2024)

2.5.3 Global Anti-VEGF Intravitreal Drugs Sale Price by Application (2019-2024)

3 GLOBAL BY COMPANY

3.1 Global Anti-VEGF Intravitreal Drugs Breakdown Data by Company

3.1.1 Global Anti-VEGF Intravitreal Drugs Annual Sales by Company (2019-2024)

3.1.2 Global Anti-VEGF Intravitreal Drugs Sales Market Share by Company (2019-2024)

3.2 Global Anti-VEGF Intravitreal Drugs Annual Revenue by Company (2019-2024)

3.2.1 Global Anti-VEGF Intravitreal Drugs Revenue by Company (2019-2024)

3.2.2 Global Anti-VEGF Intravitreal Drugs Revenue Market Share by Company (2019-2024)

3.3 Global Anti-VEGF Intravitreal Drugs Sale Price by Company

3.4 Key Manufacturers Anti-VEGF Intravitreal Drugs Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers Anti-VEGF Intravitreal Drugs Product Location Distribution

3.4.2 Players Anti-VEGF Intravitreal Drugs Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)

3.6 New Products and Potential Entrants

3.7 Market M&A Activity & Strategy

4 WORLD HISTORIC REVIEW FOR ANTI-VEGF INTRAVITREAL DRUGS BY GEOGRAPHIC REGION

4.1 World Historic Anti-VEGF Intravitreal Drugs Market Size by Geographic Region (2019-2024)

4.1.1 Global Anti-VEGF Intravitreal Drugs Annual Sales by Geographic Region (2019-2024)

4.1.2 Global Anti-VEGF Intravitreal Drugs Annual Revenue by Geographic Region (2019-2024)

4.2 World Historic Anti-VEGF Intravitreal Drugs Market Size by Country/Region (2019-2024)

4.2.1 Global Anti-VEGF Intravitreal Drugs Annual Sales by Country/Region

(2019-2024)

4.2.2 Global Anti-VEGF Intravitreal Drugs Annual Revenue by Country/Region

(2019-2024)

4.3 Americas Anti-VEGF Intravitreal Drugs Sales Growth

4.4 APAC Anti-VEGF Intravitreal Drugs Sales Growth

4.5 Europe Anti-VEGF Intravitreal Drugs Sales Growth

4.6 Middle East & Africa Anti-VEGF Intravitreal Drugs Sales Growth

5 AMERICAS

5.1 Americas Anti-VEGF Intravitreal Drugs Sales by Country

5.1.1 Americas Anti-VEGF Intravitreal Drugs Sales by Country (2019-2024)

5.1.2 Americas Anti-VEGF Intravitreal Drugs Revenue by Country (2019-2024)

5.2 Americas Anti-VEGF Intravitreal Drugs Sales by Type (2019-2024)

5.3 Americas Anti-VEGF Intravitreal Drugs Sales by Application (2019-2024)

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC Anti-VEGF Intravitreal Drugs Sales by Region

6.1.1 APAC Anti-VEGF Intravitreal Drugs Sales by Region (2019-2024)

6.1.2 APAC Anti-VEGF Intravitreal Drugs Revenue by Region (2019-2024)

6.2 APAC Anti-VEGF Intravitreal Drugs Sales by Type (2019-2024)

6.3 APAC Anti-VEGF Intravitreal Drugs Sales by Application (2019-2024)

6.4 China

6.5 Japan

6.6 South Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

6.10 China Taiwan

7 EUROPE

7.1 Europe Anti-VEGF Intravitreal Drugs by Country

7.1.1 Europe Anti-VEGF Intravitreal Drugs Sales by Country (2019-2024)

- 7.1.2 Europe Anti-VEGF Intravitreal Drugs Revenue by Country (2019-2024)
- 7.2 Europe Anti-VEGF Intravitreal Drugs Sales by Type (2019-2024)
- 7.3 Europe Anti-VEGF Intravitreal Drugs Sales by Application (2019-2024)
- 7.4 Germany
- 7.5 France
- 7.6 UK
- 7.7 Italy
- 7.8 Russia

8 MIDDLE EAST & AFRICA

- 8.1 Middle East & Africa Anti-VEGF Intravitreal Drugs by Country
 - 8.1.1 Middle East & Africa Anti-VEGF Intravitreal Drugs Sales by Country (2019-2024)
 - 8.1.2 Middle East & Africa Anti-VEGF Intravitreal Drugs Revenue by Country (2019-2024)
- 8.2 Middle East & Africa Anti-VEGF Intravitreal Drugs Sales by Type (2019-2024)
- 8.3 Middle East & Africa Anti-VEGF Intravitreal Drugs Sales by Application (2019-2024)
- 8.4 Egypt
- 8.5 South Africa
- 8.6 Israel
- 8.7 Turkey
- 8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

- 9.1 Market Drivers & Growth Opportunities
- 9.2 Market Challenges & Risks
- 9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

- 10.1 Raw Material and Suppliers
- 10.2 Manufacturing Cost Structure Analysis of Anti-VEGF Intravitreal Drugs
- 10.3 Manufacturing Process Analysis of Anti-VEGF Intravitreal Drugs
- 10.4 Industry Chain Structure of Anti-VEGF Intravitreal Drugs

11 MARKETING, DISTRIBUTORS AND CUSTOMER

- 11.1 Sales Channel

- 11.1.1 Direct Channels
- 11.1.2 Indirect Channels
- 11.2 Anti-VEGF Intravitreal Drugs Distributors
- 11.3 Anti-VEGF Intravitreal Drugs Customer

12 WORLD FORECAST REVIEW FOR ANTI-VEGF INTRAVITREAL DRUGS BY GEOGRAPHIC REGION

- 12.1 Global Anti-VEGF Intravitreal Drugs Market Size Forecast by Region
 - 12.1.1 Global Anti-VEGF Intravitreal Drugs Forecast by Region (2025-2030)
 - 12.1.2 Global Anti-VEGF Intravitreal Drugs Annual Revenue Forecast by Region (2025-2030)
- 12.2 Americas Forecast by Country (2025-2030)
- 12.3 APAC Forecast by Region (2025-2030)
- 12.4 Europe Forecast by Country (2025-2030)
- 12.5 Middle East & Africa Forecast by Country (2025-2030)
- 12.6 Global Anti-VEGF Intravitreal Drugs Forecast by Type (2025-2030)
- 12.7 Global Anti-VEGF Intravitreal Drugs Forecast by Application (2025-2030)

13 KEY PLAYERS ANALYSIS

- 13.1 Roche
 - 13.1.1 Roche Company Information
 - 13.1.2 Roche Anti-VEGF Intravitreal Drugs Product Portfolios and Specifications
 - 13.1.3 Roche Anti-VEGF Intravitreal Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
 - 13.1.4 Roche Main Business Overview
 - 13.1.5 Roche Latest Developments
- 13.2 Novartis
 - 13.2.1 Novartis Company Information
 - 13.2.2 Novartis Anti-VEGF Intravitreal Drugs Product Portfolios and Specifications
 - 13.2.3 Novartis Anti-VEGF Intravitreal Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
 - 13.2.4 Novartis Main Business Overview
 - 13.2.5 Novartis Latest Developments
- 13.3 Biogen
 - 13.3.1 Biogen Company Information
 - 13.3.2 Biogen Anti-VEGF Intravitreal Drugs Product Portfolios and Specifications
 - 13.3.3 Biogen Anti-VEGF Intravitreal Drugs Sales, Revenue, Price and Gross Margin

(2019-2024)

13.3.4 Biogen Main Business Overview

13.3.5 Biogen Latest Developments

13.4 Coherus BioSciences

13.4.1 Coherus BioSciences Company Information

13.4.2 Coherus BioSciences Anti-VEGF Intravitreal Drugs Product Portfolios and Specifications

13.4.3 Coherus BioSciences Anti-VEGF Intravitreal Drugs Sales, Revenue, Price and Gross Margin (2019-2024)

13.4.4 Coherus BioSciences Main Business Overview

13.4.5 Coherus BioSciences Latest Developments

13.5 Regeneron Pharmaceuticals

13.5.1 Regeneron Pharmaceuticals Company Information

13.5.2 Regeneron Pharmaceuticals Anti-VEGF Intravitreal Drugs Product Portfolios and Specifications

13.5.3 Regeneron Pharmaceuticals Anti-VEGF Intravitreal Drugs Sales, Revenue, Price and Gross Margin (2019-2024)

13.5.4 Regeneron Pharmaceuticals Main Business Overview

13.5.5 Regeneron Pharmaceuticals Latest Developments

13.6 Samsung Bioepis

13.6.1 Samsung Bioepis Company Information

13.6.2 Samsung Bioepis Anti-VEGF Intravitreal Drugs Product Portfolios and Specifications

13.6.3 Samsung Bioepis Anti-VEGF Intravitreal Drugs Sales, Revenue, Price and Gross Margin (2019-2024)

13.6.4 Samsung Bioepis Main Business Overview

13.6.5 Samsung Bioepis Latest Developments

13.7 Biocon Biologics

13.7.1 Biocon Biologics Company Information

13.7.2 Biocon Biologics Anti-VEGF Intravitreal Drugs Product Portfolios and Specifications

13.7.3 Biocon Biologics Anti-VEGF Intravitreal Drugs Sales, Revenue, Price and Gross Margin (2019-2024)

13.7.4 Biocon Biologics Main Business Overview

13.7.5 Biocon Biologics Latest Developments

13.8 Qilu Pharma

13.8.1 Qilu Pharma Company Information

13.8.2 Qilu Pharma Anti-VEGF Intravitreal Drugs Product Portfolios and Specifications

13.8.3 Qilu Pharma Anti-VEGF Intravitreal Drugs Sales, Revenue, Price and Gross

Margin (2019-2024)

13.8.4 Qilu Pharma Main Business Overview

13.8.5 Qilu Pharma Latest Developments

13.9 Chengdu Kanghong Pharmaceutical

13.9.1 Chengdu Kanghong Pharmaceutical Company Information

13.9.2 Chengdu Kanghong Pharmaceutical Anti-VEGF Intravitreal Drugs Product Portfolios and Specifications

13.9.3 Chengdu Kanghong Pharmaceutical Anti-VEGF Intravitreal Drugs Sales, Revenue, Price and Gross Margin (2019-2024)

13.9.4 Chengdu Kanghong Pharmaceutical Main Business Overview

13.9.5 Chengdu Kanghong Pharmaceutical Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

LIST OF TABLES

Table 1. Anti-VEGF Intravitreal Drugs Annual Sales CAGR by Geographic Region (2019, 2023 & 2030) & (\$ millions)

Table 2. Anti-VEGF Intravitreal Drugs Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & (\$ millions)

Table 3. Major Players of Ranibizumab

Table 4. Major Players of Aflibercept

Table 5. Major Players of Conbercept

Table 6. Major Players of Brolucizumab

Table 7. Major Players of Faricimab

Table 8. Major Players of Other

Table 9. Global Anti-VEGF Intravitreal Drugs Sales by Type (2019-2024) & (K Dose)

Table 10. Global Anti-VEGF Intravitreal Drugs Sales Market Share by Type (2019-2024)

Table 11. Global Anti-VEGF Intravitreal Drugs Revenue by Type (2019-2024) & (\$ million)

Table 12. Global Anti-VEGF Intravitreal Drugs Revenue Market Share by Type (2019-2024)

Table 13. Global Anti-VEGF Intravitreal Drugs Sale Price by Type (2019-2024) & (US\$/Dose)

Table 14. Global Anti-VEGF Intravitreal Drugs Sale by Application (2019-2024) & (K Dose)

Table 15. Global Anti-VEGF Intravitreal Drugs Sale Market Share by Application (2019-2024)

Table 16. Global Anti-VEGF Intravitreal Drugs Revenue by Application (2019-2024) & (\$ million)

Table 17. Global Anti-VEGF Intravitreal Drugs Revenue Market Share by Application (2019-2024)

Table 18. Global Anti-VEGF Intravitreal Drugs Sale Price by Application (2019-2024) & (US\$/Dose)

Table 19. Global Anti-VEGF Intravitreal Drugs Sales by Company (2019-2024) & (K Dose)

Table 20. Global Anti-VEGF Intravitreal Drugs Sales Market Share by Company (2019-2024)

Table 21. Global Anti-VEGF Intravitreal Drugs Revenue by Company (2019-2024) & (\$ millions)

Table 22. Global Anti-VEGF Intravitreal Drugs Revenue Market Share by Company (2019-2024)

Table 23. Global Anti-VEGF Intravitreal Drugs Sale Price by Company (2019-2024) & (US\$/Dose)

Table 24. Key Manufacturers Anti-VEGF Intravitreal Drugs Producing Area Distribution and Sales Area

Table 25. Players Anti-VEGF Intravitreal Drugs Products Offered

Table 26. Anti-VEGF Intravitreal Drugs Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)

Table 27. New Products and Potential Entrants

Table 28. Market M&A Activity & Strategy

Table 29. Global Anti-VEGF Intravitreal Drugs Sales by Geographic Region (2019-2024) & (K Dose)

Table 30. Global Anti-VEGF Intravitreal Drugs Sales Market Share Geographic Region (2019-2024)

Table 31. Global Anti-VEGF Intravitreal Drugs Revenue by Geographic Region (2019-2024) & (\$ millions)

Table 32. Global Anti-VEGF Intravitreal Drugs Revenue Market Share by Geographic Region (2019-2024)

Table 33. Global Anti-VEGF Intravitreal Drugs Sales by Country/Region (2019-2024) & (K Dose)

Table 34. Global Anti-VEGF Intravitreal Drugs Sales Market Share by Country/Region (2019-2024)

Table 35. Global Anti-VEGF Intravitreal Drugs Revenue by Country/Region (2019-2024) & (\$ millions)

Table 36. Global Anti-VEGF Intravitreal Drugs Revenue Market Share by Country/Region (2019-2024)

Table 37. Americas Anti-VEGF Intravitreal Drugs Sales by Country (2019-2024) & (K Dose)

Table 38. Americas Anti-VEGF Intravitreal Drugs Sales Market Share by Country (2019-2024)

Table 39. Americas Anti-VEGF Intravitreal Drugs Revenue by Country (2019-2024) & (\$ millions)

Table 40. Americas Anti-VEGF Intravitreal Drugs Sales byType (2019-2024) & (K Dose)

Table 41. Americas Anti-VEGF Intravitreal Drugs Sales by Application (2019-2024) & (K Dose)

Table 42. APAC Anti-VEGF Intravitreal Drugs Sales by Region (2019-2024) & (K Dose)

Table 43. APAC Anti-VEGF Intravitreal Drugs Sales Market Share by Region (2019-2024)

Table 44. APAC Anti-VEGF Intravitreal Drugs Revenue by Region (2019-2024) & (\$ millions)

Table 45. APAC Anti-VEGF Intravitreal Drugs Sales byType (2019-2024) & (K Dose)

Table 46. APAC Anti-VEGF Intravitreal Drugs Sales by Application (2019-2024) & (K Dose)

Table 47. Europe Anti-VEGF Intravitreal Drugs Sales by Country (2019-2024) & (K Dose)

Table 48. Europe Anti-VEGF Intravitreal Drugs Revenue by Country (2019-2024) & (\$ millions)

Table 49. Europe Anti-VEGF Intravitreal Drugs Sales byType (2019-2024) & (K Dose)

Table 50. Europe Anti-VEGF Intravitreal Drugs Sales by Application (2019-2024) & (K Dose)

Table 51. Middle East & Africa Anti-VEGF Intravitreal Drugs Sales by Country (2019-2024) & (K Dose)

Table 52. Middle East & Africa Anti-VEGF Intravitreal Drugs Revenue Market Share by Country (2019-2024)

Table 53. Middle East & Africa Anti-VEGF Intravitreal Drugs Sales byType (2019-2024) & (K Dose)

Table 54. Middle East & Africa Anti-VEGF Intravitreal Drugs Sales by Application (2019-2024) & (K Dose)

Table 55. Key Market Drivers & Growth Opportunities of Anti-VEGF Intravitreal Drugs

Table 56. Key Market Challenges & Risks of Anti-VEGF Intravitreal Drugs

Table 57. Key IndustryTrends of Anti-VEGF Intravitreal Drugs

Table 58. Anti-VEGF Intravitreal Drugs Raw Material

Table 59. Key Suppliers of Raw Materials

Table 60. Anti-VEGF Intravitreal Drugs Distributors List

Table 61. Anti-VEGF Intravitreal Drugs Customer List

- Table 62. Global Anti-VEGF Intravitreal Drugs SalesForecast by Region (2025-2030) & (K Dose)
- Table 63. Global Anti-VEGF Intravitreal Drugs RevenueForecast by Region (2025-2030) & (\$ millions)
- Table 64. Americas Anti-VEGF Intravitreal Drugs SalesForecast by Country (2025-2030) & (K Dose)
- Table 65. Americas Anti-VEGF Intravitreal Drugs Annual RevenueForecast by Country (2025-2030) & (\$ millions)
- Table 66. APAC Anti-VEGF Intravitreal Drugs SalesForecast by Region (2025-2030) & (K Dose)
- Table 67. APAC Anti-VEGF Intravitreal Drugs Annual RevenueForecast by Region (2025-2030) & (\$ millions)
- Table 68. Europe Anti-VEGF Intravitreal Drugs SalesForecast by Country (2025-2030) & (K Dose)
- Table 69. Europe Anti-VEGF Intravitreal Drugs RevenueForecast by Country (2025-2030) & (\$ millions)
- Table 70. Middle East & Africa Anti-VEGF Intravitreal Drugs SalesForecast by Country (2025-2030) & (K Dose)
- Table 71. Middle East & Africa Anti-VEGF Intravitreal Drugs RevenueForecast by Country (2025-2030) & (\$ millions)
- Table 72. Global Anti-VEGF Intravitreal Drugs SalesForecast byType (2025-2030) & (K Dose)
- Table 73. Global Anti-VEGF Intravitreal Drugs RevenueForecast byType (2025-2030) & (\$ millions)
- Table 74. Global Anti-VEGF Intravitreal Drugs SalesForecast by Application (2025-2030) & (K Dose)
- Table 75. Global Anti-VEGF Intravitreal Drugs RevenueForecast by Application (2025-2030) & (\$ millions)
- Table 76. Roche Basic Information, Anti-VEGF Intravitreal Drugs Manufacturing Base, Sales Area and Its Competitors
- Table 77. Roche Anti-VEGF Intravitreal Drugs Product Portfolios and Specifications
- Table 78. Roche Anti-VEGF Intravitreal Drugs Sales (K Dose), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2019-2024)
- Table 79. Roche Main Business
- Table 80. Roche Latest Developments
- Table 81. Novartis Basic Information, Anti-VEGF Intravitreal Drugs Manufacturing Base, Sales Area and Its Competitors
- Table 82. Novartis Anti-VEGF Intravitreal Drugs Product Portfolios and Specifications
- Table 83. Novartis Anti-VEGF Intravitreal Drugs Sales (K Dose), Revenue (\$ Million),

Price (US\$/Dose) and Gross Margin (2019-2024)

Table 84. Novartis Main Business

Table 85. Novartis Latest Developments

Table 86. Biogen Basic Information, Anti-VEGF Intravitreal Drugs Manufacturing Base, Sales Area and Its Competitors

Table 87. Biogen Anti-VEGF Intravitreal Drugs Product Portfolios and Specifications

Table 88. Biogen Anti-VEGF Intravitreal Drugs Sales (K Dose), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2019-2024)

Table 89. Biogen Main Business

Table 90. Biogen Latest Developments

Table 91. Coherus BioSciences Basic Information, Anti-VEGF Intravitreal Drugs Manufacturing Base, Sales Area and Its Competitors

Table 92. Coherus BioSciences Anti-VEGF Intravitreal Drugs Product Portfolios and Specifications

Table 93. Coherus BioSciences Anti-VEGF Intravitreal Drugs Sales (K Dose), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2019-2024)

Table 94. Coherus BioSciences Main Business

Table 95. Coherus BioSciences Latest Developments

Table 96. Regeneron Pharmaceuticals Basic Information, Anti-VEGF Intravitreal Drugs Manufacturing Base, Sales Area and Its Competitors

Table 97. Regeneron Pharmaceuticals Anti-VEGF Intravitreal Drugs Product Portfolios and Specifications

Table 98. Regeneron Pharmaceuticals Anti-VEGF Intravitreal Drugs Sales (K Dose), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2019-2024)

Table 99. Regeneron Pharmaceuticals Main Business

Table 100. Regeneron Pharmaceuticals Latest Developments

Table 101. Samsung Bioepis Basic Information, Anti-VEGF Intravitreal Drugs Manufacturing Base, Sales Area and Its Competitors

Table 102. Samsung Bioepis Anti-VEGF Intravitreal Drugs Product Portfolios and Specifications

Table 103. Samsung Bioepis Anti-VEGF Intravitreal Drugs Sales (K Dose), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2019-2024)

Table 104. Samsung Bioepis Main Business

Table 105. Samsung Bioepis Latest Developments

Table 106. Biocon Biologics Basic Information, Anti-VEGF Intravitreal Drugs Manufacturing Base, Sales Area and Its Competitors

Table 107. Biocon Biologics Anti-VEGF Intravitreal Drugs Product Portfolios and Specifications

Table 108. Biocon Biologics Anti-VEGF Intravitreal Drugs Sales (K Dose), Revenue (\$

Million), Price (US\$/Dose) and Gross Margin (2019-2024)

Table 109. Biocon Biologics Main Business

Table 110. Biocon Biologics Latest Developments

Table 111. Qilu Pharma Basic Information, Anti-VEGF Intravitreal Drugs Manufacturing Base, Sales Area and Its Competitors

Table 112. Qilu Pharma Anti-VEGF Intravitreal Drugs Product Portfolios and Specifications

Table 113. Qilu Pharma Anti-VEGF Intravitreal Drugs Sales (K Dose), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2019-2024)

Table 114. Qilu Pharma Main Business

Table 115. Qilu Pharma Latest Developments

Table 116. Chengdu Kanghong Pharmaceutical Basic Information, Anti-VEGF Intravitreal Drugs Manufacturing Base, Sales Area and Its Competitors

Table 117. Chengdu Kanghong Pharmaceutical Anti-VEGF Intravitreal Drugs Product Portfolios and Specifications

Table 118. Chengdu Kanghong Pharmaceutical Anti-VEGF Intravitreal Drugs Sales (K Dose), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2019-2024)

Table 119. Chengdu Kanghong Pharmaceutical Main Business

Table 120. Chengdu Kanghong Pharmaceutical Latest Developments

LIST OFFIGURES

Figure 1. Picture of Anti-VEGF Intravitreal Drugs

Figure 2. Anti-VEGF Intravitreal Drugs Report Years Considered

Figure 3. Research Objectives

Figure 4. Research Methodology

Figure 5. Research Process and Data Source

Figure 6. Global Anti-VEGF Intravitreal Drugs Sales Growth Rate 2019-2030 (K Dose)

Figure 7. Global Anti-VEGF Intravitreal Drugs Revenue Growth Rate 2019-2030 (\$ millions)

Figure 8. Anti-VEGF Intravitreal Drugs Sales by Geographic Region (2019, 2023 & 2030) & (\$ millions)

Figure 9. Anti-VEGF Intravitreal Drugs Sales Market Share by Country/Region (2023)

Figure 10. Anti-VEGF Intravitreal Drugs Sales Market Share by Country/Region (2019, 2023 & 2030)

Figure 11. Product Picture of Ranibizumab

Figure 12. Product Picture of Aflibercept

- Figure 13. Product Picture of Conbercept
- Figure 14. Product Picture of Brolocizumab
- Figure 15. Product Picture of Faricimab
- Figure 16. Product Picture of Other
- Figure 17. Global Anti-VEGF Intravitreal Drugs Sales Market Share by Type in 2023
- Figure 18. Global Anti-VEGF Intravitreal Drugs Revenue Market Share by Type (2019-2024)
- Figure 19. Anti-VEGF Intravitreal Drugs Consumed in Age-related Macular Degeneration
- Figure 20. Global Anti-VEGF Intravitreal Drugs Market: Age-related Macular Degeneration (2019-2024) & (K Dose)
- Figure 21. Anti-VEGF Intravitreal Drugs Consumed in Diabetic Macular Edema
- Figure 22. Global Anti-VEGF Intravitreal Drugs Market: Diabetic Macular Edema (2019-2024) & (K Dose)
- Figure 23. Anti-VEGF Intravitreal Drugs Consumed in Retinal Vein Occlusion
- Figure 24. Global Anti-VEGF Intravitreal Drugs Market: Retinal Vein Occlusion (2019-2024) & (K Dose)
- Figure 25. Anti-VEGF Intravitreal Drugs Consumed in Other
- Figure 26. Global Anti-VEGF Intravitreal Drugs Market: Other (2019-2024) & (K Dose)
- Figure 27. Global Anti-VEGF Intravitreal Drugs Sale Market Share by Application (2023)
- Figure 28. Global Anti-VEGF Intravitreal Drugs Revenue Market Share by Application in 2023
- Figure 29. Anti-VEGF Intravitreal Drugs Sales by Company in 2023 (K Dose)
- Figure 30. Global Anti-VEGF Intravitreal Drugs Sales Market Share by Company in 2023
- Figure 31. Anti-VEGF Intravitreal Drugs Revenue by Company in 2023 (\$ millions)
- Figure 32. Global Anti-VEGF Intravitreal Drugs Revenue Market Share by Company in 2023
- Figure 33. Global Anti-VEGF Intravitreal Drugs Sales Market Share by Geographic Region (2019-2024)
- Figure 34. Global Anti-VEGF Intravitreal Drugs Revenue Market Share by Geographic Region in 2023
- Figure 35. Americas Anti-VEGF Intravitreal Drugs Sales 2019-2024 (K Dose)
- Figure 36. Americas Anti-VEGF Intravitreal Drugs Revenue 2019-2024 (\$ millions)
- Figure 37. APAC Anti-VEGF Intravitreal Drugs Sales 2019-2024 (K Dose)
- Figure 38. APAC Anti-VEGF Intravitreal Drugs Revenue 2019-2024 (\$ millions)
- Figure 39. Europe Anti-VEGF Intravitreal Drugs Sales 2019-2024 (K Dose)
- Figure 40. Europe Anti-VEGF Intravitreal Drugs Revenue 2019-2024 (\$ millions)
- Figure 41. Middle East & Africa Anti-VEGF Intravitreal Drugs Sales 2019-2024 (K Dose)

Figure 42. Middle East & Africa Anti-VEGF Intravitreal Drugs Revenue 2019-2024 (\$ millions)

Figure 43. Americas Anti-VEGF Intravitreal Drugs Sales Market Share by Country in 2023

Figure 44. Americas Anti-VEGF Intravitreal Drugs Revenue Market Share by Country (2019-2024)

Figure 45. Americas Anti-VEGF Intravitreal Drugs Sales Market Share byType (2019-2024)

Figure 46. Americas Anti-VEGF Intravitreal Drugs Sales Market Share by Application (2019-2024)

Figure 47. United States Anti-VEGF Intravitreal Drugs Revenue Growth 2019-2024 (\$ millions)

Figure 48. Canada Anti-VEGF Intravitreal Drugs Revenue Growth 2019-2024 (\$ millions)

Figure 49. Mexico Anti-VEGF Intravitreal Drugs Revenue Growth 2019-2024 (\$ millions)

Figure 50. Brazil Anti-VEGF Intravitreal Drugs Revenue Growth 2019-2024 (\$ millions)

Figure 51. APAC Anti-VEGF Intravitreal Drugs Sales Market Share by Region in 2023

Figure 52. APAC Anti-VEGF Intravitreal Drugs Revenue Market Share by Region (2019-2024)

Figure 53. APAC Anti-VEGF Intravitreal Drugs Sales Market Share byType (2019-2024)

Figure 54. APAC Anti-VEGF Intravitreal Drugs Sales Market Share by Application (2019-2024)

Figure 55. China Anti-VEGF Intravitreal Drugs Revenue Growth 2019-2024 (\$ millions)

Figure 56. Japan Anti-VEGF Intravitreal Drugs Revenue Growth 2019-2024 (\$ millions)

Figure 57. South Korea Anti-VEGF Intravitreal Drugs Revenue Growth 2019-2024 (\$ millions)

Figure 58. Southeast Asia Anti-VEGF Intravitreal Drugs Revenue Growth 2019-2024 (\$ millions)

Figure 59. India Anti-VEGF Intravitreal Drugs Revenue Growth 2019-2024 (\$ millions)

Figure 60. Australia Anti-VEGF Intravitreal Drugs Revenue Growth 2019-2024 (\$ millions)

Figure 61. ChinaTaiwan Anti-VEGF Intravitreal Drugs Revenue Growth 2019-2024 (\$ millions)

Figure 62. Europe Anti-VEGF Intravitreal Drugs Sales Market Share by Country in 2023

Figure 63. Europe Anti-VEGF Intravitreal Drugs Revenue Market Share by Country (2019-2024)

Figure 64. Europe Anti-VEGF Intravitreal Drugs Sales Market Share byType (2019-2024)

Figure 65. Europe Anti-VEGF Intravitreal Drugs Sales Market Share by Application

(2019-2024)

Figure 66. Germany Anti-VEGF Intravitreal Drugs Revenue Growth 2019-2024 (\$ millions)

Figure 67. France Anti-VEGF Intravitreal Drugs Revenue Growth 2019-2024 (\$ millions)

Figure 68. UK Anti-VEGF Intravitreal Drugs Revenue Growth 2019-2024 (\$ millions)

Figure 69. Italy Anti-VEGF Intravitreal Drugs Revenue Growth 2019-2024 (\$ millions)

Figure 70. Russia Anti-VEGF Intravitreal Drugs Revenue Growth 2019-2024 (\$ millions)

Figure 71. Middle East & Africa Anti-VEGF Intravitreal Drugs Sales Market Share by Country (2019-2024)

Figure 72. Middle East & Africa Anti-VEGF Intravitreal Drugs Sales Market Share by Type (2019-2024)

Figure 73. Middle East & Africa Anti-VEGF Intravitreal Drugs Sales Market Share by Application (2019-2024)

Figure 74. Egypt Anti-VEGF Intravitreal Drugs Revenue Growth 2019-2024 (\$ millions)

Figure 75. South Africa Anti-VEGF Intravitreal Drugs Revenue Growth 2019-2024 (\$ millions)

Figure 76. Israel Anti-VEGF Intravitreal Drugs Revenue Growth 2019-2024 (\$ millions)

Figure 77. Turkey Anti-VEGF Intravitreal Drugs Revenue Growth 2019-2024 (\$ millions)

Figure 78. GCC Countries Anti-VEGF Intravitreal Drugs Revenue Growth 2019-2024 (\$ millions)

Figure 79. Manufacturing Cost Structure Analysis of Anti-VEGF Intravitreal Drugs in 2023

Figure 80. Manufacturing Process Analysis of Anti-VEGF Intravitreal Drugs

Figure 81. Industry Chain Structure of Anti-VEGF Intravitreal Drugs

Figure 82. Channels of Distribution

Figure 83. Global Anti-VEGF Intravitreal Drugs Sales Market Forecast by Region (2025-2030)

Figure 84. Global Anti-VEGF Intravitreal Drugs Revenue Market Share Forecast by Region (2025-2030)

Figure 85. Global Anti-VEGF Intravitreal Drugs Sales Market Share Forecast by Type (2025-2030)

Figure 86. Global Anti-VEGF Intravitreal Drugs Revenue Market Share Forecast by Type (2025-2030)

Figure 87. Global Anti-VEGF Intravitreal Drugs Sales Market Share Forecast by Application (2025-2030)

Figure 88. Global Anti-VEGF Intravitreal Drugs Revenue Market Share Forecast by Application (2025-2030)

I would like to order

Product name: Global Anti-VEGF Intravitreal Drugs Market Growth 2024-2030

Product link: <https://marketpublishers.com/r/GA883749D865EN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GA883749D865EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970